Best Peptides for Women Over 40 and 50: Weight, Skin, Sleep, Energy - Evidence-Ranked

Key takeaways

• No peptide has been shown to slow aging, in women or anyone else. "Anti-aging" is a marketing category, so this guide grades each option against the specific problems women over 40 and 50 bring to clinics: weight, skin, sleep and energy.
• Weight is the one goal where a peptide is the best-studied answer. Postmenopausal women on tirzepatide lost 23% of their body weight against 3% on placebo, and semaglutide lowered the combined rate of heart attacks, strokes and cardiovascular deaths by 20% in a trial whose participants averaged 62 years of age. Both are approved prescription drugs.
• For skin, the proven tools are not peptides: daily sunscreen (24% less skin aging over 4.5 years) and prescription tretinoin. A peptide moisturizer ingredient has one 12-week trial in women aged 35 to 55; injected "skin peptides" have none.
• For sleep and energy, the peptides sold to midlife women have the weakest record. A GHRH analog raised growth hormone in women aged 55 to 71 but improved well-being only in men and left sleep unchanged; NAD+ boosters raise a blood marker without improving muscle function after 60. Telephone CBT-I put 70% of menopausal women with insomnia in the no-insomnia range within eight weeks.
• Legally, a US pharmacy can dispense semaglutide and tirzepatide (compounded only for a documented need), sermorelin, tesamorelin (brand Egrifta only; it cannot be compounded), NAD+ and glutathione. CJC-1295, ipamorelin, BPC-157, epitalon, MOTS-c and injectable GHK-Cu cannot be compounded in October 2026.

Search for the best peptides for anti aging over 50, or over 40, and you get lists of injectables promising tighter skin, deeper sleep and more energy. This guide is for women in that decade or two, when perimenopause and menopause change weight, skin and sleep at once, and it starts from the fact those lists leave out: no peptide has been tested against aging itself. What has been tested is narrower, and for some goals, genuinely useful.

We rank by goal, because that is how the decision gets made, and we link out for depth: the menopause-specific companion is peptides for menopause, the broader list is best peptides for women, and the two support pages for this guide cover peptides for weight loss in women and the best injectable peptides for anti-aging.

How we ranked

Four criteria, in order. First, human evidence in women over 40, graded A to D as defined in our editorial policy: A for adequately powered randomized trials in a similar population, D for animal data or nothing. Second, legal status in the United States as of October 2026, from our legal tracker. Third, safety. Fourth, cost, from our cost guide. Popularity did not count.

One rule applies throughout: any claim that a peptide slows, stops or reverses aging gets a D, because no trial has measured an aging outcome. A compound can earn an A for a real problem, such as weight or fractures, and a D for the "anti-aging" label it is sold under.

The ranking at a glance

Weight and waist: tirzepatide and semaglutide

Midlife weight gain, and the shift of fat toward the waist around menopause, is the main reason women over 40 ask about peptides. It is also the one goal where the best-studied option is a peptide.

The question women ask is whether these drugs still work after menopause, and for tirzepatide there is a direct answer. A post hoc analysis sorted the women in three SURMOUNT trials by reproductive stage. In SURMOUNT-1, women on tirzepatide at 15 mg or the maximum tolerated dose lost 26% of their body weight before menopause, 23% in perimenopause and 23% after menopause, against 2% to 3% on placebo; waist circumference fell 20 to 22 cm against 4 to 5 cm; and 97% to 98% of women in every stage lost at least 5% (Tchang 2025). It was written largely by Lilly employees and the stages were assigned after the fact, but the result is consistent across groups.

Semaglutide holds the closest thing any peptide has to a healthspan result. SELECT enrolled 17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity but no diabetes; their mean age was 62, and 4,872 were women. Over a mean follow-up of 40 months, semaglutide 2.4 mg a week reduced the combined rate of cardiovascular death, heart attack and stroke from 8.0% to 6.5% (hazard ratio 0.80), while 16.6% stopped the drug for adverse events against 8.2% on placebo (Lincoff 2023). That is grade A evidence for fewer heart events in that population. It is not evidence that semaglutide slows aging.

Legal status and cost. Both are approved drugs. Since the shortages ended, compounded copies are legal only for a patient with a documented need the approved product cannot meet. Wegovy costs $349 a month for cash buyers and Zepbound $299 to $449 by dose; compounded versions run $150 to $350.

Who it is for: a woman with a BMI of 30 or more, or 27 or more with a weight-related condition, who expects long-term treatment. The details that are specific to women, including contraception in perimenopause, hair shedding, lean mass and bone, are in peptides for weight loss in women.

Bone: teriparatide, if osteoporosis is diagnosed

Bone is not in this guide's title, but after 50 it belongs on the list. Hormone therapy prevents bone loss and fracture, and for women under 60 or within ten years of menopause its benefit-risk balance for that purpose is favorable (NAMS 2022). For a woman who already has osteoporosis, teriparatide, the first 34 amino acids of parathyroid hormone, has fracture-endpoint data: in 1,637 postmenopausal women with prior vertebral fractures, 20 micrograms a day for a median of 21 months cut new vertebral fractures from 14% to 5% and nonvertebral fragility fractures from 6% to 3%, with occasional nausea and headache (Neer 2001). It is an ordinary prescription for a diagnosed disease, chosen after a DXA scan, not a wellness peptide. Abaloparatide, a related drug, is covered in the menopause guide.

Skin: sunscreen and tretinoin first, topical peptides second

The benchmark. In the one randomized trial of a skincare habit with a multi-year aging endpoint, 903 adults under 55 used broad-spectrum sunscreen daily or at their own discretion for 4.5 years; the daily group showed no detectable increase in skin aging, 24% less than the discretionary group (Hughes 2013). Prescription tretinoin 0.05% cream, applied for up to two years by 204 adults with moderate to severe photodamage, improved fine and coarse wrinkling, mottled pigmentation and sallowness more than placebo, raised a marker of collagen production at 12 months, and caused no cellular atypia (Kang 2005). Both are grade A, and neither is a peptide.

The best peptide trial. Palmitoyl pentapeptide-4 (sold as Matrixyl) was tested in 93 women aged 35 to 55, the population of this guide: 12 weeks, double-blind, one side of the face treated with a moisturizer containing 3 ppm of the peptide and the other with the same moisturizer without it. The peptide side showed fewer wrinkles and fine lines on image analysis and expert grading (Robinson 2005). The authors worked for Procter & Gamble and the trial has not been independently replicated, so it earns a B.

Copper peptide. Topical GHK-Cu has consistent laboratory data, but a 2026 systematic evidence-mapping review found the clinical evidence "remains sparse": small or poorly characterized cosmetic reports, and a 13-participant study after laser resurfacing that was negative on objective endpoints. Its conclusion was "promising but unproven" (Mateescu 2026). Grade C.

Injections. No published human study has tested an injected peptide for skin appearance, and no US pharmacy may compound injectable GHK-Cu or the GLOW and KLOW blends built on it (legal tracker). IV glutathione sold for a "glow" can be compounded, but has no published trial of injected glutathione for skin, and FDA warned compounders about contaminated product in 2019 and again in August 2026; see the glutathione profile. The full ranking is in best peptides for skin.

Who it is for: a woman who already uses sunscreen and tolerates, or cannot tolerate, a retinoid, and wants a gentle add-on. Judge it at 12 weeks.

Sleep: no peptide earns a place

Sleep problems peak around the menopausal transition, and sermorelin, a growth hormone-releasing hormone (GHRH) analog, is sold for them more than for anything else. The evidence runs the other way.

The best treatment trial of a GHRH analog in older adults enrolled 10 women and 9 men aged 55 to 71: four weeks of placebo injections, then 16 weeks of the analog nightly. Growth hormone rose in both sexes, IGF-1 rose within two weeks and drifted back toward baseline by week 16, and skin thickness increased in both. Lean body mass, insulin sensitivity, general well-being and libido improved in men only, and sleep quality "was unaffected in both genders" (Khorram 1997). In the sleep laboratory, pulsed intravenous GHRH reduced REM sleep at one dose and deep stage 4 sleep at another in healthy young women, and the authors cite an earlier study in women aged 19 to 76 with the same direction of effect (Mathias 2007). Grade D for sleep in women.

What works has trials in this exact population. In MsFLASH, 106 perimenopausal and postmenopausal women aged 40 to 65 with moderate insomnia and daily hot flashes had six telephone sessions of cognitive behavioral therapy for insomnia (CBT-I) or of menopause education. At eight weeks, 70% of the CBT-I group were in the no-insomnia range against 24%, rising to 84% against 43% at 24 weeks (McCurry 2016). When night sweats are what wake a woman, hormone therapy, the most effective treatment for vasomotor symptoms, treats the night sweats (NAMS 2022). DSIP, the "sleep peptide," was voted down by FDA's compounding committee in July 2026. The full picture is in best peptides for sleep and sermorelin for women.

Energy: the weakest evidence, the most marketing

"Energy" is not a diagnosis, and fatigue in midlife women has common, testable causes: sleep broken by night sweats, iron deficiency, an underactive thyroid, sleep apnea, depression and medication side effects. A clinician who orders blood work before an energy injection is doing the useful part.

NAD+. NAD+ is a coenzyme, not a peptide, sold beside peptides as injections and IV drips. No trial has tested injected or infused NAD+ against fatigue or any other outcome in healthy adults. The oral precursors raise NAD+ in blood, but a 2025 meta-analysis of randomized trials in adults with mean ages of 61 to 83 found that NMN did not improve muscle mass, grip strength or gait speed, and concluded that current evidence does not support NMN or nicotinamide riboside for preserving muscle mass and function after 60 (Prokopidis 2025). The most interesting result was in women: in a 10-week placebo-controlled trial in postmenopausal women with prediabetes and overweight or obesity, NMN increased muscle insulin sensitivity and insulin signaling (Yoshino 2021). That is a metabolic signal from a small trial, not more energy. Grade D for energy. See the NAD+ profile.

Growth hormone and the peptides that raise it. Sermorelin, tesamorelin and the unapproved secretagogues all work by raising growth hormone, so growth hormone itself sets their ceiling. A systematic review of randomized trials in healthy older adults (mean age 69) found that growth hormone moved about 2.1 kg from fat to lean mass with no change in weight, did not change bone density or most blood lipids, and caused more soft-tissue swelling, joint pain, carpal tunnel syndrome and new diabetes; the authors concluded it "cannot be recommended as an antiaging therapy" (Liu 2007). In the GHRH-analog trial above, the well-being gains went to the men (Khorram 1997). See the sermorelin profile and HGH peptides.

"Anti-aging" claims, graded

What we excluded and why

• CJC-1295 and ipamorelin. No female data worth the name; FDA's advisory committee voted against both in late 2024, and no pharmacy may compound them. See the profile.
• BPC-157, TB-500, epitalon and MOTS-c. Recommended by FDA's committee in July 2026 over its reviewers' objections, but not permitted until FDA completes rulemaking, which it has not. None has a trial in women with an aging outcome.
• Injectable GHK-Cu and GLOW or KLOW blends. No human skin study and no legal compounded source; see the stack review.
• Kisspeptin-10 and DSIP. Kisspeptin-10 remains on FDA's Category 2 safety-risk list (FDA categories 2026); DSIP was voted down in July 2026.
• Growth hormone (somatropin) for anti-aging. The trial evidence is above, and distributing it for anti-aging is a federal crime.
• "Menopause stacks." Research-vial bundles of the compounds above; no combination has been tested, and none can be legally compounded.

How to get it

1. Name the problem first. Weight, a skin concern, insomnia, fatigue and bone loss have different treatments, and the hormone-therapy decision comes first for many women over 45 because it changes the others.
2. Use a clinician licensed in your state who will order the right tests: glucose and a weight-related history before a GLP-1, a DXA scan before a bone drug, blood work for fatigue, IGF-1 before sermorelin.
3. Ask which pharmacy fills it and on what basis. Approved drugs, including tesamorelin (brand Egrifta, which cannot be compounded), are ordinary prescriptions; sermorelin, NAD+ and glutathione come from a named, state-licensed pharmacy. A research vial is not a prescription.
4. Price the first three months with the cost guide, and compare providers in the clinic directory. The end-to-end process is in our peptide therapy guide.
5. Agree on a stopping rule before you start: a weight and side-effect check at each GLP-1 dose step, a repeat IGF-1 at 8 to 12 weeks for sermorelin, a 12-week verdict on a skin product.

Bottom line

For women over 40 and 50, the best peptides are the ones that treat a measured problem. Tirzepatide and semaglutide lead for weight and work after menopause, and semaglutide has heart-outcome data in adults with an average age of 62. Teriparatide treats diagnosed osteoporosis. For skin, sunscreen and tretinoin come first and a topical peptide is a modest add-on. For sleep and energy, the peptides sold hardest to midlife women have the least to show: CBT-I, hormone therapy for night sweats and a proper workup for fatigue have the evidence. Nothing on this list has been shown to slow aging, and anything sold as if it had should be treated as a sales claim.

Frequently asked questions

+−What is the best peptide for anti-aging?

No peptide has been shown to slow aging, so the honest answer depends on which problem you mean. For midlife weight gain, the GLP-1 drugs tirzepatide and semaglutide have the strongest evidence of any peptide, and semaglutide lowered the combined rate of heart attacks, strokes and cardiovascular deaths by 20% in a trial of 17,604 adults whose average age was 62. For skin, daily sunscreen and prescription tretinoin outperform every peptide; the best-tested peptide is a topical moisturizer ingredient, palmitoyl pentapeptide-4. Injectables sold as anti-aging peptides have no human trials for aging.

+−What are the best peptides for women over 40?

For weight, a GLP-1 drug if you meet the BMI criteria: the trials that proved them enrolled mostly women in their mid-40s. For low sexual desire while still premenopausal, bremelanotide (Vyleesi) is approved, with a small effect. For skin, a topical peptide moisturizer is a reasonable add-on to sunscreen and a retinoid. Women in their 40s can still conceive: GLP-1 drugs must be stopped in pregnancy, and tirzepatide makes the pill less reliable for four weeks after starting and after each dose increase.

+−What are the best peptides for women over 50?

The same GLP-1 drugs work after menopause: in a SURMOUNT analysis, postmenopausal women on tirzepatide lost 23% of their body weight against 3% on placebo. For diagnosed osteoporosis at high fracture risk, teriparatide, a peptide fragment of parathyroid hormone, cut new vertebral fractures from 14% to 5% in postmenopausal women. Bremelanotide is not indicated after menopause, and sermorelin's benefits in the one trial that enrolled older women went to the men.

+−Do peptides actually work for anti-aging?

Some peptides work for specific conditions; none has been shown to work against aging. The closest evidence comes from growth hormone itself, which many 'anti-aging' peptides try to raise: in healthy older adults it shifted about 2 kg from fat to lean mass without changing weight, bone density or most blood lipids, and caused more swelling, joint pain, carpal tunnel syndrome and new diabetes. A peptide that raises growth hormone inherits that ceiling.

+−What peptide will make you look younger?

None that you inject. The best peptide skin trial is topical: 93 women aged 35 to 55 had fewer fine lines after 12 weeks on the side of the face treated with palmitoyl pentapeptide-4. Topical copper peptide (GHK-Cu) is promising but unproven. For comparison, daily sunscreen produced 24% less skin aging over 4.5 years, and prescription tretinoin improved wrinkles over two years. No injected peptide has been tested for skin appearance.

+−What's the downside of taking peptides?

It depends on the product. Approved drugs have known side effects: GLP-1 drugs cause nausea and other gut symptoms, tirzepatide hair loss was reported by 7.1% of women in its trials, and tirzepatide reduces oral contraceptive absorption. Compounded peptides are not reviewed by FDA for potency or sterility, and FDA warned compounders about contaminated glutathione injections in 2019 and again in August 2026. Research vials have no label, no prescriber and no legal path to human use. The commonest downside is paying for a claim no trial supports.

+−Do peptides help with sleep in menopause?

No peptide has evidence for menopausal sleep. A growth hormone-releasing hormone analog left sleep quality unchanged in women aged 55 to 71, and GHRH itself impaired sleep in laboratory studies of women. Telephone-delivered cognitive behavioral therapy for insomnia does work: in 106 perimenopausal and postmenopausal women with hot flashes, 70% were in the no-insomnia range after eight weeks against 24% with menopause education. When night sweats are the cause, hormone therapy treats them.

+−Is NAD+ good for energy after 50?

There is no evidence that it is. No trial has tested NAD+ injections or IV drips against fatigue or any other outcome in healthy adults. Oral NAD+ precursors raise NAD+ in the blood, but a 2025 meta-analysis of trials in adults with mean ages of 61 to 83 found no benefit for muscle mass, grip strength or walking speed. A small trial in postmenopausal women with prediabetes found better muscle insulin sensitivity, a metabolic signal rather than more energy. At-home NAD+ injections cost $105 to $350 a month in October 2026.

Sources

1. StudyTchang BG et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring) 2025;33:851-60. (2025)
2. StudyLincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-32. (2023)
3. StudyNeer RM et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41. (2001)
4. GuidelineThe 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767-94. (2022)
5. StudyHughes MC, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med 2013;158:781-90. (2013)
6. StudyKang S et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin Dermatol 2005;6:245-53. (2005)
7. StudyRobinson LR et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci 2005;27:155-60. (Authors affiliated with Procter & Gamble.) (2005)
8. ReviewMateescu DM et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap (systematic evidence-mapping review). Pharmaceutics 2026;18:1077. (2026)
9. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
10. StudyMathias S et al. Systemic growth hormone-releasing hormone (GHRH) impairs sleep in healthy young women. Psychoneuroendocrinology 2007;32:1021-7. (2007)
11. StudyMcCurry SM et al. Telephone-based cognitive behavioral therapy for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms: a MsFLASH randomized clinical trial. JAMA Intern Med 2016;176:913-20. (2016)
12. StudyYoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021;372:1224-9. (2021)
13. ReviewProkopidis K et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2025;16:e13799. (2025)
14. ReviewLiu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-15. (2007)
15. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)